Verily, an Alphabet precision health technology company, and Kyverna Therapeutics, a clinical-stage cell therapy company, have announced a multi-year collaboration. The initial focus is on deploying Verily’s advanced Immune Profiler to identify treatment-response biomarkers in autoimmune patients undergoing Phase 1 clinical trials for Kyverna’s KYV-101 in the US and Europe.

Unveiling the Biological Basis of Immune Reset

“B cell depletion using CAR T-cells represents a new frontier with curative potential for autoimmune patients, and together we will be uncovering the biological basis of the immune reset that confers durable therapeutic response in these patients,” stated Charlie Kim, head of molecular science at Verily. Verily’s Immune Profiler, equipped with high-resolution molecular phenotyping and computational analytics, will give a broad and detailed view of immune functions over the time course of CAR T-cell therapy.

Kyverna’s Contributions: Emerging Patient Data and Samples

“We are excited to explore our emerging patient data set, which will enable us to generate a first look into the biology underlying immune reset after administration of CAR T-cell therapy,” said James Chung, chief medical officer at Kyverna. Kyverna’s existing network of research-ready participants and sample library from treating autoimmune patients will augment this study.

Innovating Real-world Clinical Research

Additionally, both companies will utilize digital tools to shift the paradigm in evidence generation, employing a participant-centered study design that uses data from real-world settings in addition to traditional study sites. “We are pleased to partner with Verily based on our shared vision to create the future landscape of clinical research, and to enable broader data collection from real-world settings that may contribute to regulatory decision-making,” commented Peter Maag, CEO of Kyverna.

Comprehensive Understanding of Autoimmune Disease

“This collaboration links Verily’s deep molecular capabilities with its extensive suite of tools for real-world evidence generation, providing a comprehensive and detailed understanding of the biology and participant experience with this new therapeutic modality in autoimmune disease,” added Amy Abernethy, president of product development and chief medical officer at Verily. The collaboration aims to develop specific solutions for the needs of autoimmune patients treated with CAR T-cell therapy.

  Alphabet, Amy Abernethy, CAR T cell therapy, Charlie Kim, KYV-101, Kyverna Therapeutics, USA, Verily